ATE168267T1 - Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten - Google Patents

Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten

Info

Publication number: ATE168267T1
Authority: AT; Austria
Prior art keywords: fatty acid; compositions containing; unsaturated fatty; cholesterol esters; containing cholesterol
Prior art date: 1993-01-06

Application number

AT93310599T

Other languages

English (en)

Inventor

David Frederick Horrobin

Original Assignee

Scotia Holdings Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-01-06

Filing date

1993-12-29

Publication date

1998-08-15

1993-12-29 Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc

1998-08-15 Application granted granted Critical

1998-08-15 Publication of ATE168267T1 publication Critical patent/ATE168267T1/de

Links

150000001840 cholesterol esters Chemical class 0.000 title 1
239000000203 mixture Substances 0.000 title 1
235000021122 unsaturated fatty acids Nutrition 0.000 title 1
150000004670 unsaturated fatty acids Chemical class 0.000 title 1
235000014113 dietary fatty acids Nutrition 0.000 abstract 2
229930195729 fatty acid Natural products 0.000 abstract 2
239000000194 fatty acid Substances 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
-1 Cholesterol fatty acid esters Chemical class 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
235000004626 essential fatty acids Nutrition 0.000 abstract 1
150000004665 fatty acids Chemical class 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Fats And Perfumes (AREA)
Cosmetics (AREA)
Optical Recording Or Reproduction (AREA)
Medicinal Preparation (AREA)

AT93310599T 1993-01-06 1993-12-29 Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten ATE168267T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB939300125A GB9300125D0 (en)	1993-01-06	1993-01-06	Compositions containing esters of unsaturated fatty acids

Publications (1)

Publication Number	Publication Date
ATE168267T1 true ATE168267T1 (de)	1998-08-15

Family

ID=10728334

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93310599T ATE168267T1 (de)	1993-01-06	1993-12-29	Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten

Country Status (17)

Country	Link
US (1)	US5604216A (de)
EP (1)	EP0606012B1 (de)
JP (1)	JPH06234644A (de)
KR (1)	KR940018088A (de)
CN (1)	CN1096197A (de)
AT (1)	ATE168267T1 (de)
AU (1)	AU673555B2 (de)
CA (1)	CA2112824A1 (de)
DE (1)	DE69319710T2 (de)
DK (1)	DK0606012T3 (de)
ES (1)	ES2119871T3 (de)
GB (1)	GB9300125D0 (de)
MY (1)	MY110765A (de)
NO (1)	NO940035D0 (de)
NZ (1)	NZ250583A (de)
RU (1)	RU2142468C1 (de)
ZA (1)	ZA9425B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6107499A (en) *	1988-02-26	2000-08-22	Neuromedica, Inc.	Dopamine analog amide
US5795909A (en) *	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en)	1996-05-22	2003-06-10	Protarga, Inc.	Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6197764B1 (en)	1997-11-26	2001-03-06	Protarga, Inc.	Clozapine compositions and uses thereof
US6153653A (en) *	1997-11-26	2000-11-28	Protarga, Inc.	Choline compositions and uses thereof
US5977174A (en) *	1997-11-26	1999-11-02	Neuromedica, Inc.	Cholinergic compositions and uses thereof
US5955459A (en) *	1997-11-26	1999-09-21	Neuromedica, Inc.	Fatty acid-antipsychotic compositions and uses thereof
US7413759B2 (en) *	1998-05-21	2008-08-19	Beech-Nut Nutrition Corporation	Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US6149964A (en) *	1998-05-21	2000-11-21	Beech-Nut Nutrition Corporation	Egg yolk-containing baby food compositions and methods therefor
US7141266B2 (en) *	1998-05-21	2006-11-28	Beech-Nut Nutrition Corporation	Baby-food compositions enhancing visual acuity and methods therefor
US6579551B1 (en)	1998-05-21	2003-06-17	Beech-Nut Nutrition Corporation	Baby-food compositions containing egg yolk and methods therefor
NZ333817A (en) *	1998-08-25	2000-09-29	Mcneil Ppc Inc	Process for preparing stanol/sterol fatty acid esters such as beta sitosterol fatty acid esters, useful in reducing cholesterol levels
US5892068A (en) *	1998-08-25	1999-04-06	Mcneil-Ppc, Inc.	Preparation of sterol and stanol-esters
GB9901809D0 (en)	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
AU2006201772B2 (en) *	1999-01-27	2010-02-04	Amarin Neuroscience Limited	Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
US7235583B1 (en) *	1999-03-09	2007-06-26	Luitpold Pharmaceuticals, Inc.,	Fatty acid-anticancer conjugates and uses thereof
JP2000355538A (ja) *	1999-04-15	2000-12-26	Kanegafuchi Chem Ind Co Ltd	ペルオキシゾーム活性化剤応答性受容体アゴニスト
DE60028368T2 (de) *	1999-04-15	2007-02-01	Kaneka Corp.	Agonisten des peroxisom aktivator-responsiven rezeptors
AU6813700A (en) *	1999-08-30	2001-03-26	Ocean Nutrition Canada Ltd.	A nutritional supplement for lowering serum triglyceride and cholesterol levels
US6998501B1 (en) *	1999-08-30	2006-02-14	Ocean Nutrition Canada Limited	Nutritional supplement for lowering serum triglyceride and cholesterol levels
US20030206958A1 (en) *	2000-12-22	2003-11-06	Cattaneo Maurizio V.	Chitosan biopolymer for the topical delivery of active agents
ATE384518T1 (de) *	2000-01-31	2008-02-15	Haerting S A	Zusammensetzungen enthaltend phytosterol- und policosanolester von fettsäuren zur herabsetzung des cholesterol- und triglyceridspiegels
KR20010091499A (ko) *	2000-03-16	2001-10-23	김용범	레이저 그래픽 디스플레이 장치
JP4594489B2 (ja) *	2000-03-31	2010-12-08	備前化成株式会社	特異的殺癌細胞剤及びこれを配合してなる組成物
EP1423107B1 (de) *	2001-03-23	2012-05-09	Luitpold Pharmaceuticals, Inc.	Fettalkohol-arzneimittel-konjugate
JP2005500988A (ja)	2001-03-23	2005-01-13	ルイトポルド・ファーマシューティカルズ・インコーポレーテッド	脂肪族アミン薬物複合体
JP2003048831A (ja) *	2001-08-02	2003-02-21	Suntory Ltd	脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
DE10154221A1 (de) *	2001-11-07	2003-05-15	Max Delbrueck Centrum	Mittel zur Behandlung von Läsionen des Nervensystems
CN1816287A (zh) *	2003-01-31	2006-08-09	宝洁公司	改善哺乳动物角质组织外观的方法
US20050123500A1 (en) *	2003-01-31	2005-06-09	The Procter & Gamble Company	Means for improving the appearance of mammalian hair and nails
ATE420887T1 (de) *	2003-04-02	2009-01-15	Us Gov Health & Human Serv	Cholesterol enthaltende verbindungen und deren verwendung als immunogen gegen borellia burgdorferi
CA2529735C (en) *	2003-06-20	2012-07-10	Mochida Pharmaceutical Co., Ltd.	Eicosapentaenoic acid for preventing or treating varicose veins of lower extremities
CA2436650A1 (en) *	2003-08-06	2005-02-06	Naturia Inc.	Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
AU2005240189A1 (en) *	2004-05-06	2005-11-17	Ivrea Pharmaceuticals, Inc.	Particles for the delivery of active agents
US20060141046A1 (en) *	2004-05-06	2006-06-29	Ivrea Pharmaceuticals, Inc.	Particles for the delivery of active agents
CN103211807A (zh) *	2005-07-08	2013-07-24	Dsmip资产公司	用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸
US20080110624A1 (en) *	2005-07-15	2008-05-15	Halliburton Energy Services, Inc.	Methods for controlling water and particulate production in subterranean wells
ITMI20052377A1 (it) *	2005-12-13	2007-06-14	Anna Petroni	Medicamento a base di monoestere di steroidi con acidi grassi a catena lunga
FR2902659A1 (fr) *	2006-06-23	2007-12-28	Pierre Fabre Medicament Sa	Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
PL2334295T3 (pl)	2008-09-02	2017-12-29	Amarin Pharmaceuticals Ltd	Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
KR20140007973A (ko)	2009-02-10	2014-01-20	아마린 파마, 인크.	고중성지방혈증 치료 방법
SG10201912687WA (en)	2009-04-29	2020-02-27	Amarin Pharmaceuticals Ie Ltd	Stable Pharmaceutical Composition And Methods Of Using Same
CN104042617A (zh)	2009-04-29	2014-09-17	阿马里纳药物爱尔兰有限公司	含有epa和心血管剂的药物组合物以及使用其的方法
EP3698781A1 (de)	2009-06-15	2020-08-26	Amarin Pharmaceuticals Ireland Limited	Zusammensetzungen mit eicosapentaensäure zur behandlung von myokardinfarktionen bei patienten mit gleichzeitiger statin-therapie
RU2758369C2 (ru)	2009-09-23	2021-10-28	Амарин Фармасьютикалз Айрлэнд Лимитед	Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения
CN102656153B (zh) *	2009-10-29	2015-02-18	延世大学校产学协力团	新型血管渗漏阻断剂
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en)	2010-11-29	2019-10-25	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en)	2011-11-07	2013-05-16	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US9827219B2 (en)	2012-01-06	2017-11-28	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
LT4338805T (lt)	2012-06-29	2025-09-25	Amarin Pharmaceuticals Ireland Limited	Eikozapentaeno rūgšties etilo esteris, skirtas panaudoti mažinant nemirtino miokardo infarkto riziką subjektui, gydomam statinais
US9717741B2 (en)	2012-10-11	2017-08-01	Anaplasi Pharmaceuticals Llc	Method and compositions for treating psoriasis
EP3305299B1 (de) *	2012-10-11	2020-04-29	Anaplasi Pharmaceuticals LLC	Verfahren und zusammensetzungen zur behandlung von schuppenflechte
US20150265566A1 (en)	2012-11-06	2015-09-24	Amarin Pharmaceuticals Ireland Limited	Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
JP6224203B2 (ja) *	2016-12-08	2017-11-01	アナプラシファーマシューティカルズエルエルシー	乾癬を治療するための組成物
TW201900160A (zh)	2017-05-19	2019-01-01	愛爾蘭商艾瑪琳製藥愛爾蘭有限公司	用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
JP6491293B2 (ja) *	2017-10-04	2019-03-27	アナプラシファーマシューティカルズエルエルシー	乾癬を治療するためのエアロゾル、ムース、又はフォームの組成物
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3750535B1 (de)	2018-09-24	2025-12-31	Amarin Pharmaceuticals Ireland Limited	Verfahren zur verringerung des risikos von kardiovaskulären ereignissen in einem subjekt
JP6728425B2 (ja) *	2019-02-28	2020-07-22	アナプラシファーマシューティカルズエルエルシー	乾癬を治療するためのクリーム、ローション、又はゲルの組成物
BR112022009189A2 (pt)	2019-11-12	2022-07-26	Amarin Pharmaceuticals Ie Ltd	Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
AU2022263358A1 (en)	2021-04-21	2023-11-30	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3174870D1 (en) *	1981-03-13	1986-07-31	Green Cross Corp	Water-soluble cholesterol derivatives
GB8524275D0 (en) *	1985-10-02	1985-11-06	Efamol Ltd	Pharmaceutical & dietary compositions
SU1456442A1 (ru) *	1987-04-03	1989-02-07	Житомирский Государственный Педагогический Институт Им.И.Франко	(Холестерилоксикарбонилметил)трифенилфосфонийхлорид в качестве полупродукта в синтезе холестериловых эфиров непредельных карбоновых кислот

1993
- 1993-01-06 GB GB939300125A patent/GB9300125D0/en active Pending
- 1993-12-23 NZ NZ250583A patent/NZ250583A/xx unknown
- 1993-12-29 DK DK93310599T patent/DK0606012T3/da active
- 1993-12-29 DE DE69319710T patent/DE69319710T2/de not_active Expired - Fee Related
- 1993-12-29 AT AT93310599T patent/ATE168267T1/de not_active IP Right Cessation
- 1993-12-29 ES ES93310599T patent/ES2119871T3/es not_active Expired - Lifetime
- 1993-12-29 EP EP93310599A patent/EP0606012B1/de not_active Expired - Lifetime
- 1993-12-30 AU AU52763/93A patent/AU673555B2/en not_active Ceased
1994
- 1994-01-04 MY MYPI94000009A patent/MY110765A/en unknown
- 1994-01-04 ZA ZA9425A patent/ZA9425B/xx unknown
- 1994-01-05 CA CA002112824A patent/CA2112824A1/en not_active Abandoned
- 1994-01-05 NO NO940035A patent/NO940035D0/no unknown
- 1994-01-05 RU RU94000061A patent/RU2142468C1/ru active
- 1994-01-06 KR KR1019940000159A patent/KR940018088A/ko not_active Ceased
- 1994-01-06 CN CN94100242A patent/CN1096197A/zh active Pending
- 1994-01-06 JP JP6000338A patent/JPH06234644A/ja active Pending
- 1994-01-06 US US08/178,553 patent/US5604216A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0606012B1 (de)	1998-07-15
ZA9425B (en)	1994-08-19
US5604216A (en)	1997-02-18
JPH06234644A (ja)	1994-08-23
MY110765A (en)	1999-03-31
GB9300125D0 (en)	1993-03-03
DE69319710T2 (de)	1999-03-11
RU2142468C1 (ru)	1999-12-10
AU673555B2 (en)	1996-11-14
CN1096197A (zh)	1994-12-14
NO940035L (de)	1994-07-07
EP0606012A1 (de)	1994-07-13
NZ250583A (en)	1997-08-22
NO940035D0 (no)	1994-01-05
ES2119871T3 (es)	1998-10-16
CA2112824A1 (en)	1994-07-07
AU5276393A (en)	1994-07-14
DE69319710D1 (de)	1998-08-20
KR940018088A (ko)	1994-08-16
DK0606012T3 (da)	1999-04-19

Legal Events

Date	Code	Title	Description
1999-05-15	UEP	Publication of translation of european patent specification
2000-09-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE168267T1 (de)	1998-08-15	Zusammensetzungen, die cholesterin ester von ungesättigten fettsäure enthalten
RU94000061A (ru)	1995-08-27	Эфиры холестерина и ненасыщенных жирных кислот, способ лечения и фармацевтическая или косметическая композиция
ATE106867T1 (de)	1994-06-15	13-trans-retinsäureester.
TW429145B (en)	2001-04-11	Pharmaceutical composition for treating schizophrenia, tardive dyskinesia, depression, and alzheimer's disease comprising EPA/SA
AU7053494A (en)	1995-01-03	Method of treating coronary vascular disease using docosahexaenoic acid
NO940277L (no)	1994-07-28	Triglycerider og blandinger av slike
CA2144312A1 (en)	1994-04-14	Unsaturated aliphatic dicarboxylic acids
IT1176916B (it)	1987-08-18	Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
DE69312579D1 (de)	1997-09-04	Arzneimittel zur Behandlung von Vulva-Dystrophie oder Vaginaltrockenheit
ATE138639T1 (de)	1996-06-15	L-carnitin- und alkanoyl-l-carnitin-ester mit glykolsäure oder ihre ester und diese enthaltende pharmazeutische zusammensetzungen zur behandlung von dermatosen
AU1821888A (en)	1989-01-05	Treatment or prevention of memory loss using essential fatty acid compositions
DE59504267D1 (de)	1998-12-24	Härten von ungesättigten fetten, fettsäuren oder fettsäureestern
AU554413B2 (en)	1986-08-21	Linoleic acid and essential fatty acid compositions as
FI883310A0 (fi)	1988-07-12	Rengoeringsmedelkomposition och dess anvaendning.
ES8400464A1 (es)	1983-11-01	Procedimiento para la obtencion de resinas de poliester insaturadas, tixotropicas.
DE3760876D1 (en)	1989-11-30	Cyclohexane-, cyclohexene- and cyclohexadiene, bicycloû2.2.1¨heptane and bicyclo û2.2.1¨heptenecarboxylic acid esters, and also perfume compositions and perfumed products which contain one or more of said compounds as perfume component
DE3784738D1 (de)	1993-04-15	Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
ATE113291T1 (de)	1994-11-15	Polyaromatische ester von makroliden antibiotika und linkosamiden antibiotika, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen und kosmetischen zusammensetzungen.
ES2191671T3 (es)	2003-09-16	Esteres de 1,4-dihidropiridina 4-fenil-3-sustituidos.
DE3851937D1 (de)	1994-12-01	Nicht gesättigte cycloaliphatische Ester von makroliden Antibiotika und linkosamiden Antibiotika, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen und kosmetischen Zusammensetzungen.